NIH Cuts Funding for Studies on Vaccine Hesitancy and Acceptance
TUESDAY, March 11, 2025 -- The National Institutes of Health (NIH) is cutting or canceling more than 40 grants focused on vaccine hesitancy and ways to increase vaccine acceptance, according to an email obtained by The Washington Post.
The message — sent Monday by Michelle Bulls, director of the Office of Policy for Extramural Research Administration — directed staff to terminate funding immediately. It said the research no longer aligns with agency priorities, according to The Post.
The email spelled out specific language to be used in the termination notice: “It is the policy of NIH not to prioritize research activities that focuses gaining scientific knowledge on why individuals are hesitant to be vaccinated and/or explore ways to improve vaccine interest and commitment. … Therefore, the award is terminated.”
The move dovetails with new leadership at the U.S. Department of Health and Human Services (HHS). New HHS Secretary Robert F. Kennedy Jr. has long questioned vaccine safety and has promoted scientifically debunked claims linking vaccines to autism.
It's unclear if Kennedy played a direct role in the decision, but his appointment has unsettled the medical research community.
Experts warn the funding cuts come at a critical time. The U.S. has reported 222 measles cases across 12 states this year, with vaccination rates among kindergartners declining since 2019. One child has died from measles and another death is under investigation, according to the U.S. Centers for Disease Control and Prevention (CDC).
Researcher Manoj Sharma had a CDC grant that ended last year to evaluate vaccine hesitancy and told The Post that the current outbreak underscores the importance of continued research.
“There is an urgent need to enhance vaccine acceptance behavior, especially due to the potential resurgence of measles and COVID-19 still looming,” said Sharma, a professor of social and behavioral health at the University of Nevada at Las Vegas.
Delesha Carpenter, a researcher at the University of North Carolina at Chapel Hill, has spent three years studying COVID vaccine hesitancy through a previous NIH grant.
She fears the termination of research will limit efforts to provide the public with reliable vaccine information.
“If we take away research on vaccine hesitancy, we’re also going to be taking away the ability to provide people with the best information about whether the vaccine is in their best interest,” Carpenter said. “They still have the decision to make.”
The NIH is also reducing funding for research on transgender issues, diversity and inclusion and Chinese universities.
The Post reported that internal documents showed that last week, grants management staffers received guidance on how to terminate funding in these areas.
Sources
- The Washington Post, March 10, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
New World Screwworm Parasite Detected in Northern Mexico Near U.S. Border
FRIDAY, Sept. 26, 2025 — A dangerous parasite once eliminated in the United States has been detected in northern Mexico, close to the U.S. border. Mexico’s...
Gene Therapy Slows Huntington’s Disease in Early Trial
FRIDAY, Sept. 26, 2025 — A new gene therapy has shown promise in slowing the progression of Huntington’s disease, according to early trial results released...
Tylenol Refutes Old Post as Pregnancy Safety Debate Resurfaces
FRIDAY, Sept. 26, 2025 — The maker of Tylenol is pushing back against resurfaced claims that its popular pain reliever is unsafe for pregnant women. Kenvue, the parent...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.